Sydney, Feb 2, 2026, 16:46 AEDT — Market closed
- Sigma Healthcare closed steady at A$3.09, with intraday moves ranging from A$3.08 to A$3.12.
- The broader S&P/ASX 200 fell 1.02%, dragged lower by declines in materials and gold shares.
- Attention shifts to the RBA’s policy decision on Tuesday, with Sigma set to report half-year results on Feb. 26.
Sigma Healthcare Ltd shares closed steady at A$3.09 on Monday, defying a broader market slump that weighed on materials and tech sectors during a choppy session.
The relative calm didn’t last as Australian shares slipped into the close. The S&P/ASX 200 finished down 1.02%, weighed down by declines in gold and mining sectors.
Sigma’s defensive stance is catching eyes ahead of Tuesday’s Reserve Bank of Australia decision, which could shift rate forecasts and ripple through market valuations.
A global metals selloff played a key role. A Reuters “Instant View” summary of strategists highlighted forced selling and de-leveraging triggered by steep drops in gold and silver. Marc Velan from Lucerne Asset Management called it a “positioning washout,” not a fundamental macro change. Reuters
Sigma’s next major event is its FY26 half-year results. The company plans to release figures for the six months ending Dec. 31, 2025, on Thursday, Feb. 26, with a webcast briefing scheduled for 10 a.m. AEDT.
Interest rates are the key near-term macro driver. The RBA plans to release its monetary policy decision statement at 2:30 p.m. AEDT on Tuesday, accompanied by a Statement on Monetary Policy. A media briefing will follow at 3:30 p.m., per the central bank’s official calendar.
Sigma, a pharmacy franchisor as well as a pharmaceutical wholesaler and distributor, was transformed by its Chemist Warehouse deal completed through a scheme of arrangement last year.
Quiet days can flip quickly. A surprise from the RBA or fresh turmoil in commodities and broader risk assets might easily overwhelm stock-specific drivers in the session ahead.
Traders are also eyeing any new company guidance linked to the Feb. 26 results, especially how management describes trading conditions for the second half. The market will be looking for clearer insight into the merged group’s run-rate performance.
